Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/1346-8138.14615 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sweet Syndrome: A Retrospective Analysis of 21 Patients.
J Coll Physicians Surg Pak
January 2025
Department of Dermatology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China.
Sweet syndrome, also known as acute febrile neutrophilic dermatosis, is a rare condition characterised by fever, leucocytosis, and painful skin lesions. This retrospective study analysed 21 patients with Sweet syndrome treated at the Affiliated Hospital of Xuzhou Medical University from January 2015 to June 2022. The study aimed to investigate the aetiology, clinicopathological features, and treatment outcomes.
View Article and Find Full Text PDFWound care of Sweet syndrome in a patient with anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: a case report.
J Wound Care
January 2025
The First Affiliated Hospital of Guangzhou University of Chinese Medicine, 510405, Guangzhou, China.
Sweet syndrome (SS), which is characterised by fever and erythematous tender skin lesions, has been shown to be associated with lymphoma. However, there are limited reported experiences on the wound care of SS in patients with lymphoma. This case report presents the wound care of SS in a patient with anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALK+ALCL).
View Article and Find Full Text PDFCutaneous Adverse Drug Reactions Associated with SGLT2 Inhibitors.
J Clin Med
December 2024
Department of Cardiology-Internal Medicine and Ambulatory Care, Prevention and Cardiovascular Recovery, "Victor Babeș" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
Diabetes is a complex global healthcare burden involving multiple organ systems with its prevalence on the rise. SGLT2 inhibitors enhance glucose excretion. The objective of our literature review was to determine the association between cutaneous adverse drug reactions (CADRs) and the use of SGLT2 inhibitors.
View Article and Find Full Text PDFClinical Variant of Serpentine Supravenous Hyperpigmentation Following Subcutaneous Bortezomib Injection.
HCA Healthc J Med
December 2024
University of North Texas Health Science Center at Fort Worth, Fort Worth, TX.
Introduction: Bortezomib is a reversible proteasome inhibitor that is a first-line chemotherapeutic agent for multiple myeloma. Bortezomib can be administered intravenously or subcutaneously with similar efficacy. Subcutaneous administration has fewer side effects.
View Article and Find Full Text PDFHydroxychloroquine-induced Sweet's Syndrome: A Case Report and Literature Review.
Acta Derm Venereol
January 2025
Dermatology Department, Unidade Local de Saúde Santa Maria, Lisbon, Portugal; Dermatology University Clinic, Faculty of Medicine, University of Lisbon, Lisbon, Portugal; Dermatology Research Unit, Instituto de Medicina Molecular, University of Lisbon, Lisbon, Portugal.
Sweet's syndrome (or acute febrile dermatosis) is a neutrophilic dermatosis with a characteristic presentation encompassing specific clinical (fever and erythemato-violaceous oedematous papules, plaques and nodules), laboratory (neutrophilia and increased inflammatory markers), and histological (dermal neutrophilic infiltrate without vasculitis) features. Its pathophysiology is poorly understood but there seems to be an auto-inflammatory component related to mutations in inflammasome genes. It has been subdivided into its classic form, malignancy-associated, and drug-induced, according to its aetiology.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!